{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:49:04Z","timestamp":1790275744295,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s11940-008-0044-7","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T15:25:08Z","timestamp":1227713108000},"page":"420-428","source":"Crossref","is-referenced-by-count":24,"title":["Spinal muscular atrophy: Advances in research and consensus on care of patients"],"prefix":"10.1007","volume":"10","author":[{"given":"Ching H.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Lunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,11,25]]},"reference":[{"key":"44_CR1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0960-8966(91)90052-T","volume":"1","author":"T.L. Munsat","year":"1991","unstructured":"Munsat TL: International SMA Collaboration. Neuromuscul Disord 1991, 1:81.","journal-title":"Neuromuscul Disord"},{"key":"44_CR2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","volume":"22","author":"B.S. Russman","year":"2007","unstructured":"Russman BS: Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 2007, 22:946\u2013951.","journal-title":"J Child Neurol"},{"key":"44_CR3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S. Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, et al.: Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155\u2013165.","journal-title":"Cell"},{"key":"44_CR4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/geno.1996.0147","volume":"32","author":"L. Burglen","year":"1996","unstructured":"Burglen L, Lefebvre S, Clermont O, et al.: Structure and organization of the human survival motor neurone (SMN) gene. Genomics 1996, 32:479\u2013482.","journal-title":"Genomics"},{"key":"44_CR5","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/4.10.1927","volume":"4","author":"E. Hahnen","year":"1995","unstructured":"Hahnen E, Forkert R, Marke C, et al.: Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet 1995, 4:1927\u20131933.","journal-title":"Hum Mol Genet"},{"key":"44_CR6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","volume":"9","author":"C.L. Lorson","year":"2000","unstructured":"Lorson CL, Androphy EJ: An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 2000, 9:259\u2013265.","journal-title":"Hum Mol Genet"},{"key":"44_CR7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.neuint.2004.04.005","volume":"45","author":"H.C. Chang","year":"2004","unstructured":"Chang HC, Hung WC, Chuang YJ, Jong YJ: Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin\/proteasome pathway. Neurochem Int 2004, 45:1107\u20131112.","journal-title":"Neurochem Int"},{"key":"44_CR8","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/hmg\/10.24.2841","volume":"10","author":"C. Andreassi","year":"2001","unstructured":"Andreassi C, Jarecki J, Zhou J, et al.: Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001, 10:2841\u20132849.","journal-title":"Hum Mol Genet"},{"key":"44_CR9","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","volume":"98","author":"J.G. Chang","year":"2001","unstructured":"Chang JG, Hsieh-Li HM, Jong YJ, et al.: Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 2001, 98:9808\u20139813.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"44_CR10","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","volume":"12","author":"L. Brichta","year":"2003","unstructured":"Brichta L, Hofmann Y, Hahnen E, et al.: Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003, 12:2481\u20132489.","journal-title":"Hum Mol Genet"},{"key":"44_CR11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","volume":"54","author":"C.J. Sumner","year":"2003","unstructured":"Sumner CJ, Huynh TN, Markowitz JA, et al.: Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003, 54:647\u2013654.","journal-title":"Ann Neurol"},{"key":"44_CR12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.20548","volume":"58","author":"S.M. Grzeschik","year":"2005","unstructured":"Grzeschik SM, Ganta M, Prior TW, et al.: Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 2005, 58:194\u2013202.","journal-title":"Ann Neurol"},{"key":"44_CR13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","volume":"12","author":"C. Andreassi","year":"2004","unstructured":"Andreassi C, Angelozzi C, Tiziano FD, et al.: Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004, 12:59\u201365.","journal-title":"Eur J Hum Genet"},{"key":"44_CR14","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/hmg\/ddi205","volume":"14","author":"J. Jarecki","year":"2005","unstructured":"Jarecki J, Chen X, Bernardino A, et al.: Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 2005, 14:2003\u20132018.","journal-title":"Hum Mol Genet"},{"key":"44_CR15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00439-006-0245-7","volume":"120","author":"V.B. Mattis","year":"2006","unstructured":"Mattis VB, Rai R, Wang J, et al.: Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet 2006, 120:589\u2013601.","journal-title":"Hum Genet"},{"key":"44_CR16","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.chembiol.2004.08.024","volume":"11","author":"M.R. Lunn","year":"2004","unstructured":"Lunn MR, Root DE, Martino AM, et al.: Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol 2004, 11:1489\u20131493.","journal-title":"Chem Biol"},{"key":"44_CR17","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1073\/pnas.160181697","volume":"97","author":"Y. Hofmann","year":"2000","unstructured":"Hofmann Y, Lorson CL, Stamm S, et al.: Htra2-1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci U S A 2000, 97:9618\u20139623.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"44_CR18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0092-8674(00)80211-1","volume":"89","author":"M.J. Pazin","year":"1997","unstructured":"Pazin MJ, Kadonaga JT: What\u2019s up and down with histone deacetylation and transcription? Cell 1997, 89:325\u2013328.","journal-title":"Cell"},{"key":"44_CR19","first-page":"2292","volume":"7","author":"J. Gilbert","year":"2001","unstructured":"Gilbert J, Baker SD, Bowling MK, et al.: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001, 7:2292\u20132300.","journal-title":"Clin Cancer Res"},{"key":"44_CR20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","volume":"98","author":"E. Hahnen","year":"2006","unstructured":"Hahnen E, Eyupoglu IY, Brichta L, et al.: In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 2006, 98:193\u2013202.","journal-title":"J Neurochem"},{"key":"44_CR21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","volume":"117","author":"A.M. Avila","year":"2007","unstructured":"Avila AM, Burnett BG, Taye AA, et al.: Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007, 117:659\u2013671.","journal-title":"J Clin Invest"},{"key":"44_CR22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1527-3458.1997.tb00318.x","volume":"3","author":"J. Stutzmann","year":"1997","unstructured":"Stutzmann J, Wahl F, Pratt J, et al.: Neuroprotective profile of riluzole in in vivo models of acute neurodegenerative disease. CNS Drug Rev 1997, 3:83\u2013101.","journal-title":"CNS Drug Rev"},{"key":"44_CR23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mus.10455","volume":"28","author":"H. Haddad","year":"2003","unstructured":"Haddad H, Cifuentes-Diaz C, Miroglio A, et al.: Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle Nerve 2003, 28:432\u2013437.","journal-title":"Muscle Nerve"},{"key":"44_CR24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ng0598-63","volume":"19","author":"C.L. Lorson","year":"1998","unstructured":"Lorson CL, Strasswimmer J, Yao JM, et al.: SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 1998, 19:63\u201366.","journal-title":"Nat Genet"},{"key":"44_CR25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ana.20052","volume":"55","author":"M.T. Howard","year":"2004","unstructured":"Howard MT, Anderson CB, Fass U, et al.: Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 2004, 55:422\u2013426.","journal-title":"Ann Neurol"},{"key":"44_CR26","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pbio.0050073","volume":"54","author":"Y. Hua","year":"2007","unstructured":"Hua Y, Vickers TA, Baker BF, et al.: Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 2007, 5(4):e73.","journal-title":"PLoS Biol"},{"key":"44_CR27","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1073\/pnas.0633863100","volume":"100","author":"L.A. Skordis","year":"2003","unstructured":"Skordis LA, Dunckley MG, Yue B, et al.: Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A 2003, 100:4114\u20134119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"44_CR28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nsb887","volume":"10","author":"L. Cartegni","year":"2003","unstructured":"Cartegni L, Krainer AR: Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003, 10:120\u2013125.","journal-title":"Nat Struct Biol"},{"key":"44_CR29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.nmd.2006.12.001","volume":"17","author":"P. Kaufmann","year":"2007","unstructured":"Kaufmann P, Muntoni F: Issues in SMA clinical trial design: The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design. Neuromuscul Disord 2007, 17:499\u2013505.","journal-title":"Neuromuscul Disord"},{"key":"44_CR30","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nmd.2005.07.005","volume":"15","author":"E. Bertini","year":"2005","unstructured":"Bertini E, Burghes A, Bushby K, et al.: 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11\u201313 February 2005, Naarden, The Netherlands. Neuromuscul Disord 2005, 15:802\u2013816.","journal-title":"Neuromuscul Disord"},{"key":"44_CR31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mus.10166","volume":"26","author":"L. Merlini","year":"2002","unstructured":"Merlini L, Mazzone ES, Solari A, Morandi L: Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve 2002, 26:64\u201370.","journal-title":"Muscle Nerve"},{"key":"44_CR32","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archneur.60.8.1130","volume":"60","author":"S.T. Iannaccone","year":"2003","unstructured":"Iannaccone ST, Hynan LS: Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol 2003, 60:1130\u20131136.","journal-title":"Arch Neurol"},{"key":"44_CR33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.nmd.2006.03.015","volume":"16","author":"K.J. Krosschell","year":"2006","unstructured":"Krosschell KJ, Maczulski JA, Crawford TO, et al.: A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 2006, 16:417\u2013426.","journal-title":"Neuromuscul Disord"},{"key":"44_CR34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1212\/01.wnl.0000201929.56928.13","volume":"66","author":"C.J. Sumner","year":"2006","unstructured":"Sumner CJ, Kolb SJ, Harmison GG, et al.: SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 2006, 66:1067\u20131073.","journal-title":"Neurology"},{"key":"44_CR35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1212\/01.wnl.0000252934.70676.ab","volume":"68","author":"L.R. Simard","year":"2007","unstructured":"Simard LR, Belanger MC, Morissette S, et al.: Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology 2007, 68:451\u2013456.","journal-title":"Neurology"},{"key":"44_CR36","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.chembiol.2005.09.005","volume":"12","author":"M.R. Lunn","year":"2005","unstructured":"Lunn MR, Stockwell BR: Chemical genetics and orphan genetic diseases. Chem Biol 2005, 12:1063\u20131073.","journal-title":"Chem Biol"},{"key":"44_CR37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(02)00835-8","volume":"110","author":"H. Wichterle","year":"2002","unstructured":"Wichterle H, Lieberam I, Porter JA, Jessell TM: Directed differentiation of embryonic stem cells into motor neurons. Cell 2002, 110:385\u2013397.","journal-title":"Cell"},{"key":"44_CR38","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1523\/JNEUROSCI.23-12-05131.2003","volume":"23","author":"D.A. Kerr","year":"2003","unstructured":"Kerr DA, Llado J, Shamblott MJ, et al.: Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. J Neurosci 2003, 23:5131\u20135140.","journal-title":"J Neurosci"},{"key":"44_CR39","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1073\/pnas.0401103101","volume":"101","author":"J.M. Harper","year":"2004","unstructured":"Harper JM, Krishnan C, Darman JS, et al.: Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci U S A 2004, 101:7123\u20137128.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"44_CR40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","volume":"191","author":"R.G. Miller","year":"2001","unstructured":"Miller RG, Moore DH, Dronsky V, et al.: A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 2001, 191:127\u2013131.","journal-title":"J Neurol Sci"},{"key":"44_CR41","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.60.11.1601","volume":"60","author":"B.S. Russman","year":"2003","unstructured":"Russman BS, Iannaccone ST, Samaha FJ: A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 2003, 60:1601\u20131603.","journal-title":"Arch Neurol"},{"key":"44_CR42","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","volume":"59","author":"M. Kinali","year":"2002","unstructured":"Kinali M, Mercuri M, Main M, et al.: Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002, 59:609\u2013610.","journal-title":"Neurology"},{"key":"44_CR43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00002060-200009000-00005","volume":"79","author":"A.C. Tzeng","year":"2000","unstructured":"Tzeng AC, Cheng J, Fryczynski H, et al.: A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil 2000, 79:435\u2013440.","journal-title":"Am J Phys Med Rehabil"},{"key":"44_CR44","unstructured":"European Spinal Muscular Atrophy Randomized Clinical Trial II (EUROSMART II). www.enmc.org\/workshop\/?id=73 . Accessed August 6, 2008."},{"key":"44_CR45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","volume":"13","author":"C. Brahe","year":"2005","unstructured":"Brahe C, Vitali T, Tiziano FD, et al.: Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005, 13:256\u2013259.","journal-title":"Eur J Hum Genet"},{"key":"44_CR46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2003.11.006","volume":"14","author":"E. Mercuri","year":"2004","unstructured":"Mercuri E, Bertini E, Messina S, et al.: Pilot trial of phenyl-butyrate in spinal muscular atrophy. Neuromuscul Disord 2004, 14:130\u2013135.","journal-title":"Neuromuscul Disord"},{"key":"44_CR47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","volume":"68","author":"E. Mercuri","year":"2007","unstructured":"Mercuri E, Bertini E, Messina S, et al.: Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007, 68:51\u201355.","journal-title":"Neurology"},{"key":"44_CR48","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","volume":"59","author":"L. Brichta","year":"2006","unstructured":"Brichta L, Holker I, Haug K, et al.: In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 2006, 59:970\u2013975.","journal-title":"Ann Neurol"},{"key":"44_CR49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","volume":"67","author":"C.C. Weihl","year":"2006","unstructured":"Weihl CC, Connolly AM, Pestronk A: Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy. Neurology 2006, 67:500\u2013501.","journal-title":"Neurology"},{"key":"44_CR50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2007.11.012","volume":"268","author":"W.C. Liang","year":"2008","unstructured":"Liang WC, You CY, Chang JG, et al.: The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci 2008, 268:87\u201394.","journal-title":"J Neurol Sci"},{"key":"44_CR51","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"C.H. Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, et al.: Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007, 22:1027\u20131049. Available at http:\/\/jcn.sagepub.com\/cgi\/content\/abstract\/22\/8\/1027 .","journal-title":"J Child Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-008-0044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-008-0044-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-008-0044-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:53Z","timestamp":1559437013000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-008-0044-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1007\/s11940-008-0044-7","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}